Skip to content

Dr. Gearóid Tuohy

Nanoscope Therapeutics Inc., have announced key results for Phase 2b (“RESTORE”) for the treatment of retinitis pigmentosa (RP) using optogenetic therapy. 

Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported key data from a Phase 2b multi-centre RCT (NCT04945772) of “MCO-010” (sonpiretigene isteparvovec), an… Read More »Nanoscope Therapeutics Inc., have announced key results for Phase 2b (“RESTORE”) for the treatment of retinitis pigmentosa (RP) using optogenetic therapy. 

Analysis reports the treatment burden of intravitreal anti-VEGF injections among a Norwegian cohort of patients and caregivers on nAMD.

Researchers at the Institute of Basic Medical Sciences, University of Oslo, the Norwegian Association of the Blind and Partially Sighted, Oslo, and Roche Norway (F Hoffmann-La… Read More »Analysis reports the treatment burden of intravitreal anti-VEGF injections among a Norwegian cohort of patients and caregivers on nAMD.

US “LIGHTSITE III” clinical trial data on photo-biomodulation (PBT) treatment of dry AMD has reported vision improvement for 24 months.

A US company, LumiThera Inc., based in Seattle, WA has reported summary trial data on photo-biomodulation, termed “LIGHTSITE III” study, conducted by a multi-centre clinical… Read More »US “LIGHTSITE III” clinical trial data on photo-biomodulation (PBT) treatment of dry AMD has reported vision improvement for 24 months.

Two new RP/LCA-specific instruments have reported strong evidence for psychometric validity on measures with RP/LCA adults and caregivers of children.

Researchers led by clinical scientists at the Department of Clinical Neurosciences, University of Oxford, UK, has reported that, previously, there have been no disease-specific instruments… Read More »Two new RP/LCA-specific instruments have reported strong evidence for psychometric validity on measures with RP/LCA adults and caregivers of children.